Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22007493,T(max),"The main pharmacokinetics parameters of the sustained-release tablets and conventional tablets were as follows, respectively: T(max)(3.67 +/- 1.51) hand (1.58 +/- 0.38) h; C(max) (5.04 +/- 1.19) mg/L and (4.56 +/- 1.70) mg/L; AUC(0 --> infinity) (32.82 +/- 9.88) mg/L x h and (29.84 +/- 14.27) mg/L x h.",[Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007493/),h,3.67,15018,DB01400,Neostigmine
,22007493,T(max),"The main pharmacokinetics parameters of the sustained-release tablets and conventional tablets were as follows, respectively: T(max)(3.67 +/- 1.51) hand (1.58 +/- 0.38) h; C(max) (5.04 +/- 1.19) mg/L and (4.56 +/- 1.70) mg/L; AUC(0 --> infinity) (32.82 +/- 9.88) mg/L x h and (29.84 +/- 14.27) mg/L x h.",[Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007493/),h,1.58,15019,DB01400,Neostigmine
,22007493,C(max),"The main pharmacokinetics parameters of the sustained-release tablets and conventional tablets were as follows, respectively: T(max)(3.67 +/- 1.51) hand (1.58 +/- 0.38) h; C(max) (5.04 +/- 1.19) mg/L and (4.56 +/- 1.70) mg/L; AUC(0 --> infinity) (32.82 +/- 9.88) mg/L x h and (29.84 +/- 14.27) mg/L x h.",[Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007493/),[mg] / [l],5.04,15020,DB01400,Neostigmine
,22007493,C(max),"The main pharmacokinetics parameters of the sustained-release tablets and conventional tablets were as follows, respectively: T(max)(3.67 +/- 1.51) hand (1.58 +/- 0.38) h; C(max) (5.04 +/- 1.19) mg/L and (4.56 +/- 1.70) mg/L; AUC(0 --> infinity) (32.82 +/- 9.88) mg/L x h and (29.84 +/- 14.27) mg/L x h.",[Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007493/),[mg] / [l],4.56,15021,DB01400,Neostigmine
,22007493,AUC(0 --> infinity),"The main pharmacokinetics parameters of the sustained-release tablets and conventional tablets were as follows, respectively: T(max)(3.67 +/- 1.51) hand (1.58 +/- 0.38) h; C(max) (5.04 +/- 1.19) mg/L and (4.56 +/- 1.70) mg/L; AUC(0 --> infinity) (32.82 +/- 9.88) mg/L x h and (29.84 +/- 14.27) mg/L x h.",[Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007493/),[mg] / [h·l],32.82,15022,DB01400,Neostigmine
,22007493,AUC(0 --> infinity),"The main pharmacokinetics parameters of the sustained-release tablets and conventional tablets were as follows, respectively: T(max)(3.67 +/- 1.51) hand (1.58 +/- 0.38) h; C(max) (5.04 +/- 1.19) mg/L and (4.56 +/- 1.70) mg/L; AUC(0 --> infinity) (32.82 +/- 9.88) mg/L x h and (29.84 +/- 14.27) mg/L x h.",[Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007493/),[mg] / [h·l],29.84,15023,DB01400,Neostigmine
,22007493,relative bioavailability,The relative bioavailability of the neostigmine bromide sustained-release tablets was 115.4%.,[Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007493/),%,115.4,15024,DB01400,Neostigmine
,6119998,ED50,The ED50 of neostigmine (dose which produced a 50% antagonism) when antagonizing Org NC 45 and pancuronium was 0.011 mg kg-1 and 0.010 mg kg-1 respectively.,Antagonism of org NC 45 (vecuronium) and pancuronium neuromuscular blockade by neostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119998/),[mg] / [kg],0.011,18027,DB01400,Neostigmine
,6119998,ED50,The ED50 of neostigmine (dose which produced a 50% antagonism) when antagonizing Org NC 45 and pancuronium was 0.011 mg kg-1 and 0.010 mg kg-1 respectively.,Antagonism of org NC 45 (vecuronium) and pancuronium neuromuscular blockade by neostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119998/),[mg] / [kg],0.010,18028,DB01400,Neostigmine
,1662599,Onset time,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,2.3,57479,DB01400,Neostigmine
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,109,57480,DB01400,Neostigmine
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,2.8,57481,DB01400,Neostigmine
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,39,57482,DB01400,Neostigmine
,1662599,Terminal half-lives,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,101.5,57483,DB01400,Neostigmine
,1662599,Terminal half-lives,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,179,57484,DB01400,Neostigmine
,1662599,distribution volumes at steady state,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[l] / [kg],0.339,57485,DB01400,Neostigmine
,1662599,distribution volumes at steady state,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[l] / [kg],0.506,57486,DB01400,Neostigmine
,1662599,plasma clearance,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[ml] / [kg·min],3.4,57487,DB01400,Neostigmine
,1662599,plasma clearance,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[ml] / [kg·min],2.5,57488,DB01400,Neostigmine
,23824662,peak sugammadex concentration,"The mean peak sugammadex concentration was 66.5 μg/mL, with exposure similar in the sevoflurane/propofol groups.",Effect of sugammadex on QT/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23824662/),[μg] / [ml],66.5,65938,DB01400,Neostigmine
,24357101,flow rate,All samples were extracted with ethyl acetate and separated on a C₁₈ column under gradient elution with a mobile phase consisting of methanol and water containing 5 mm ammonium acetate at a flow rate of 0.6 mL/min.,A sensitive LC-MS/MS method for simultaneous determination of R-bambuterol and its active metabolite R-terbutaline in human plasma and urine with application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24357101/),[ml] / [min],0.6,69703,DB01400,Neostigmine
,11913717,AUC,"After 1-min intravenous infusion of parathion to rats pretreated with neostigmine, the AUC of parathion (65.1 versus 74.3 microg min/ml) was significantly greater and the CL of parathion (45.1 versus 40.4 ml/min/kg) was significantly slower than those in control rats.",Effects of neostigmine on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913717/),[min·μg] / [ml],65.1,78502,DB01400,Neostigmine
,11913717,AUC,"After 1-min intravenous infusion of parathion to rats pretreated with neostigmine, the AUC of parathion (65.1 versus 74.3 microg min/ml) was significantly greater and the CL of parathion (45.1 versus 40.4 ml/min/kg) was significantly slower than those in control rats.",Effects of neostigmine on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913717/),[min·μg] / [ml],74.3,78503,DB01400,Neostigmine
,11913717,CL,"After 1-min intravenous infusion of parathion to rats pretreated with neostigmine, the AUC of parathion (65.1 versus 74.3 microg min/ml) was significantly greater and the CL of parathion (45.1 versus 40.4 ml/min/kg) was significantly slower than those in control rats.",Effects of neostigmine on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913717/),[ml] / [kg·min],45.1,78504,DB01400,Neostigmine
,11913717,CL,"After 1-min intravenous infusion of parathion to rats pretreated with neostigmine, the AUC of parathion (65.1 versus 74.3 microg min/ml) was significantly greater and the CL of parathion (45.1 versus 40.4 ml/min/kg) was significantly slower than those in control rats.",Effects of neostigmine on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913717/),[ml] / [kg·min],40.4,78505,DB01400,Neostigmine
,11913717,activity,"Based on in vitro hepatic microsomal studies, neostigmine inhibited significantly the erythromycin N-demethylase activity (1.03 versus 0.871 nmol/mg protein/min), mainly mediated by hepatic cytochrome P450 3A in rats.",Effects of neostigmine on the pharmacokinetics of intravenous parathion in rats. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913717/),[nM] / [·mg·min],1.03,78506,DB01400,Neostigmine
,11913717,activity,"Based on in vitro hepatic microsomal studies, neostigmine inhibited significantly the erythromycin N-demethylase activity (1.03 versus 0.871 nmol/mg protein/min), mainly mediated by hepatic cytochrome P450 3A in rats.",Effects of neostigmine on the pharmacokinetics of intravenous parathion in rats. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913717/),[nM] / [·mg·min],0.871,78507,DB01400,Neostigmine
less,216382,disposition (distribution) half-life,The fast disposition (distribution) half-life of the drug was invariably less than 1 min; the slow disposition (elimination) half-life ranged from 15.4--31.7 min.,Pharmacokinetics and pharmacological effects of neostigmine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/216382/),min,1,80568,DB01400,Neostigmine
,216382,disposition (elimination) half-life,The fast disposition (distribution) half-life of the drug was invariably less than 1 min; the slow disposition (elimination) half-life ranged from 15.4--31.7 min.,Pharmacokinetics and pharmacological effects of neostigmine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/216382/),min,15.4--31.7,80569,DB01400,Neostigmine
,6842398,volume of the central compartment,The volume of the central compartment was 412 +/- 352 ml/kg (mean +/- S.D.) and the volume of distribution at steady state was 2517 +/- 363 ml/kg.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg],412,92560,DB01400,Neostigmine
,6842398,volume of distribution at steady state,The volume of the central compartment was 412 +/- 352 ml/kg (mean +/- S.D.) and the volume of distribution at steady state was 2517 +/- 363 ml/kg.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg],2517,92561,DB01400,Neostigmine
,6842398,Initial half-lives,Initial half-lives were 1.1 +/- 0.7 and 25.4 +/- 11 min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,1.1,92562,DB01400,Neostigmine
,6842398,Initial half-lives,Initial half-lives were 1.1 +/- 0.7 and 25.4 +/- 11 min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,25.4,92563,DB01400,Neostigmine
,6842398,terminal elimination half-life,The terminal elimination half-life was 125 +/- 23 min and total clearance was 21 +/- 4 ml/kg/min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,125,92564,DB01400,Neostigmine
,6842398,total clearance,The terminal elimination half-life was 125 +/- 23 min and total clearance was 21 +/- 4 ml/kg/min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg·min],21,92565,DB01400,Neostigmine
,6842398,onset time,"The pharmacodynamic results included an onset time of 14 +/- 8 min, peak effect (maximum percentage of antagonism of twitch tension depression) 97 +/- 27% and duration of action 219 +/- 54 min.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,14,92566,DB01400,Neostigmine
,6842398,duration of action,"The pharmacodynamic results included an onset time of 14 +/- 8 min, peak effect (maximum percentage of antagonism of twitch tension depression) 97 +/- 27% and duration of action 219 +/- 54 min.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,219,92567,DB01400,Neostigmine
,6446831,half-life,In vitro experiments showed that thymoxamine had a half-life in human plasma of about only 1 min.,Plasma induced biotransformation of thymoxamine and its kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6446831/),min,1,101428,DB01400,Neostigmine
,6446831,Km,A Km-value of about 0.115 mumol ml-1 and a Vm-value of about 0.0037 mumol ml-1 min.-1 were found.,Plasma induced biotransformation of thymoxamine and its kinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6446831/),[μM] / [ml],0.115,101429,DB01400,Neostigmine
,6446831,Vm,A Km-value of about 0.115 mumol ml-1 and a Vm-value of about 0.0037 mumol ml-1 min.-1 were found.,Plasma induced biotransformation of thymoxamine and its kinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6446831/),[-1·min·μM] / [ml],0.0037,101430,DB01400,Neostigmine
,2169210,plasma clearance,"When elderly patients were compared with younger controls, the elderly exhibited a statistically significant decreased plasma clearance (5.9 +/- 2 versus 12.1 +/- 4 mL.kg-1.min-1) and a prolonged elimination half-life (84.2 +/- 17 versus 56.6 +/- 16 min).",Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),[ml] / [kg·min],5.9,104161,DB01400,Neostigmine
,2169210,plasma clearance,"When elderly patients were compared with younger controls, the elderly exhibited a statistically significant decreased plasma clearance (5.9 +/- 2 versus 12.1 +/- 4 mL.kg-1.min-1) and a prolonged elimination half-life (84.2 +/- 17 versus 56.6 +/- 16 min).",Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),[ml] / [kg·min],12.1,104162,DB01400,Neostigmine
,2169210,elimination half-life,"When elderly patients were compared with younger controls, the elderly exhibited a statistically significant decreased plasma clearance (5.9 +/- 2 versus 12.1 +/- 4 mL.kg-1.min-1) and a prolonged elimination half-life (84.2 +/- 17 versus 56.6 +/- 16 min).",Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),min,84.2,104163,DB01400,Neostigmine
,2169210,elimination half-life,"When elderly patients were compared with younger controls, the elderly exhibited a statistically significant decreased plasma clearance (5.9 +/- 2 versus 12.1 +/- 4 mL.kg-1.min-1) and a prolonged elimination half-life (84.2 +/- 17 versus 56.6 +/- 16 min).",Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),min,56.6,104164,DB01400,Neostigmine
,2169210,maximum duration of action,The maximum duration of action of edrophonium in both groups was very brief (1.3-2.2 min).,Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2169210/),min,1.3-2.2,104165,DB01400,Neostigmine
,15915024,Time to a train-of-four ratio,Time to a train-of-four ratio of 0.8 ranged from 30 to 60 min (n = 6).,Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915024/),min,0,107311,DB01400,Neostigmine
,15915024,Time to a train-of-four ratio,Time to a train-of-four ratio of 0.8 ranged from 30 to 60 min (n = 6).,Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915024/),min,30 to 60,107312,DB01400,Neostigmine
,15915024,train-of-four ratio,"Neostigmine injected after cholinesterase shortened recovery further, and a train-of-four ratio of 0.8 was reached in 10-30 min.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915024/),,0.8,107313,DB01400,Neostigmine
,3524957,Plasma clearances,Plasma clearances of the reversible quaternary cholinesterase inhibitors are in the range 0.5 to 1.0 L/h/kg and their apparent volumes of distribution range from 0.5 to 1.7 L/kg.,Clinical pharmacokinetics of cholinesterase inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[l] / [h·kg],0.5 to 1.0,120227,DB01400,Neostigmine
,3524957,apparent volumes of distribution,Plasma clearances of the reversible quaternary cholinesterase inhibitors are in the range 0.5 to 1.0 L/h/kg and their apparent volumes of distribution range from 0.5 to 1.7 L/kg.,Clinical pharmacokinetics of cholinesterase inhibitors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[l] / [kg],0.5 to 1.7,120228,DB01400,Neostigmine
,3524957,plasma elimination half-lives,"Accordingly, the drugs have short plasma elimination half-lives, in the order of 30 to 90 minutes.",Clinical pharmacokinetics of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),min,30 to 90,120229,DB01400,Neostigmine
,3524957,peak plasma concentrations,"One to two hours after oral administration of 60 mg pyridostigmine, peak plasma concentrations of 40 to 60 micrograms/L are observed, whereas the plasma concentrations of neostigmine after a 30 mg oral dose are only 1 to 5 micrograms/L.",Clinical pharmacokinetics of cholinesterase inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[μg] / [l],40 to 60,120230,DB01400,Neostigmine
,3524957,plasma concentrations,"One to two hours after oral administration of 60 mg pyridostigmine, peak plasma concentrations of 40 to 60 micrograms/L are observed, whereas the plasma concentrations of neostigmine after a 30 mg oral dose are only 1 to 5 micrograms/L.",Clinical pharmacokinetics of cholinesterase inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[μg] / [l],1 to 5,120231,DB01400,Neostigmine
,3524957,oral bioavailability,The oral bioavailability of these hydrophilic ionised compounds is low: that of pyridostigmine is approximately 10% and the value for neostigmine is even lower.,Clinical pharmacokinetics of cholinesterase inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),%,10,120232,DB01400,Neostigmine
,3524957,plasma elimination half-life,This drug too is characterised by a short plasma elimination half-life of 20 to 30 minutes.,Clinical pharmacokinetics of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),min,20 to 30,120233,DB01400,Neostigmine
,2101780,t1/2 beta,Moreover nasal administration shows a longer plasmatic elimination compared with the i.v. route (t1/2 beta e.n. = 160.04 min; t1/2 beta i.v. = 23.35 min).,Pharmacokinetic study of neostigmine after intranasal and intravenous administration in the guinea pig. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2101780/),min,160.04,122640,DB01400,Neostigmine
,2101780,t1/2 beta,Moreover nasal administration shows a longer plasmatic elimination compared with the i.v. route (t1/2 beta e.n. = 160.04 min; t1/2 beta i.v. = 23.35 min).,Pharmacokinetic study of neostigmine after intranasal and intravenous administration in the guinea pig. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2101780/),min,23.35,122641,DB01400,Neostigmine
less,7224209,rate of increase in twitch tension,Twitch tension rapidly increased to a plateau (a rate of increase in twitch tension of less than 2 per cent of control per min) which was sustained in all cases.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),%,2,142422,DB01400,Neostigmine
,7224209,time to plateau,The mean time to plateau for edrophonium was 2.9 +/- 0.21 (+/-SE) min as compared to 6.1 +/- 0.75 min for neostigmine.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,2.9,142423,DB01400,Neostigmine
,7224209,time to plateau,The mean time to plateau for edrophonium was 2.9 +/- 0.21 (+/-SE) min as compared to 6.1 +/- 0.75 min for neostigmine.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,6.1,142424,DB01400,Neostigmine
,7224209,elimination half-lives,"The elimination half-lives of edrophonium and neostigmine were 110 +/- 34 min (mean +/- SD) and 77 +/- 47 min, respectively.",Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,110,142425,DB01400,Neostigmine
,7224209,elimination half-lives,"The elimination half-lives of edrophonium and neostigmine were 110 +/- 34 min (mean +/- SD) and 77 +/- 47 min, respectively.",Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,77,142426,DB01400,Neostigmine
,7946859,infusion requirements,"During the final 15 min of infusion, the infusion requirements were 2.5 (1.1) mg kg-1 h-1.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),[mg] / [h·kg],2.5,144207,DB01400,Neostigmine
,7946859,TOF ratio,"In the five patients who were allowed to recover spontaneously, a TOF ratio of 0.7 was reached 37.9 (12.4) min after stopping the infusion of Org 9487.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),,0.7,144208,DB01400,Neostigmine
,7946859,TOF ratio,"In the five patients who were allowed to recover spontaneously, a TOF ratio of 0.7 was reached 37.9 (12.4) min after stopping the infusion of Org 9487.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),min,37.9,144209,DB01400,Neostigmine
,7946859,TOF ratio,"In the five patients who received neostigmine, a TOF ratio of 0.7 was reached after 14.5 (6.1) min.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),,0.7,144210,DB01400,Neostigmine
,7946859,Plasma clearance,Plasma clearance was 8.5 (30%) ml kg-1 min-1.,"Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),[ml] / [kg·min],8.5,144211,DB01400,Neostigmine
,7946859,Volume of distribution at steady state,Volume of distribution at steady state was 293 (55%) ml kg-1.,"Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),[ml] / [kg],293,144212,DB01400,Neostigmine
,7946859,Terminal half-life,"Terminal half-life and mean residence time were 71.7 (34%) and 33.4 (31%) min, respectively.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),min,71.7,144213,DB01400,Neostigmine
,7946859,mean residence time,"Terminal half-life and mean residence time were 71.7 (34%) and 33.4 (31%) min, respectively.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),min,33.4,144214,DB01400,Neostigmine
,7946859,Urinary excretion,Urinary excretion of Org 9487 and its metabolites was 22% in 24 h.,"Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),%,22,144215,DB01400,Neostigmine
,30823444,IC50,"The newly synthesized derivatives showed promising activities against AChE, especially compound 3b (IC50 18.1 ± 0.9 nM), which was the most promising molecule in the series, and was substantially more active than the reference drug (neostigmine methyl sulfate; IC50 2186.5 ± 98.0 nM).","Drug-1,3,4-Thiadiazole Conjugates as Novel Mixed-Type Inhibitors of Acetylcholinesterase: Synthesis, Molecular Docking, Pharmacokinetics, and ADMET Evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30823444/),nM,18.1,144469,DB01400,Neostigmine
,30823444,IC50,"The newly synthesized derivatives showed promising activities against AChE, especially compound 3b (IC50 18.1 ± 0.9 nM), which was the most promising molecule in the series, and was substantially more active than the reference drug (neostigmine methyl sulfate; IC50 2186.5 ± 98.0 nM).","Drug-1,3,4-Thiadiazole Conjugates as Novel Mixed-Type Inhibitors of Acetylcholinesterase: Synthesis, Molecular Docking, Pharmacokinetics, and ADMET Evaluation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30823444/),nM,2186.5,144470,DB01400,Neostigmine
,30823444,Ki,"The Ki of 3b (0.0031 µM) indicates that it can be very effective, even at low concentrations.","Drug-1,3,4-Thiadiazole Conjugates as Novel Mixed-Type Inhibitors of Acetylcholinesterase: Synthesis, Molecular Docking, Pharmacokinetics, and ADMET Evaluation. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30823444/),μM,0.0031,144471,DB01400,Neostigmine
,11068698,activation energy,The activation energy could be estimated from the Arrhenius plot as 15.72 kcal/mole.,Degradation kinetics of neostigmine in solution. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11068698/),[kcal] / [mole],15.72,150155,DB01400,Neostigmine
,11068698,half-life,"The half-life of 883.7 days was estimated at room temperature in 0.1 M, pH 4.9 acetate buffer solution (mu = 0.5).",Degradation kinetics of neostigmine in solution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11068698/),d,883.7,150156,DB01400,Neostigmine
,3733273,t1/2,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),min,1-2,156391,DB01400,Neostigmine
,3733273,Vd beta,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),[l] / [kg],2.6,156392,DB01400,Neostigmine
,3733273,Cl total,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),[l] / [h·kg],0.310-0.384,156393,DB01400,Neostigmine
,3733273,elimination phase half-life,"A biexponential serum decay curve of atropine was demonstrated by RIA with a very rapid distribution phase (t1/2 = 1-2 min) and a quite high tissue distribution (mean Vd beta = 2.6 l/kg), but due to the effective clearance of the drug (mean Cl total = 0.310-0.384 l/kg/h) the mean elimination phase half-life was around 6.5 hours.",Pharmacokinetics of atropine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733273/),h,6.5,156394,DB01400,Neostigmine
,7329157,Maximum plasma concentrations,Maximum plasma concentrations of pyridostigmine in the first and second groups of patients ranged from 12.4 to 64.5 ng per ml and 15.3 to 144.0 ng per ml respectively.,The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329157/),[ng] / [ml],12.4 to 64.5,175641,DB01400,Neostigmine
,7329157,Maximum plasma concentrations,Maximum plasma concentrations of pyridostigmine in the first and second groups of patients ranged from 12.4 to 64.5 ng per ml and 15.3 to 144.0 ng per ml respectively.,The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329157/),[ng] / [ml],15.3 to 144.0,175642,DB01400,Neostigmine
,6486504,ED50,The reported values for ED50 for edrophonium (obtained under similar anesthetic conditions) is 128 micrograms/kg for adults.,Clinical pharmacology of edrophonium in infants and children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[μg] / [kg],128,176742,DB01400,Neostigmine
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],17.8,176743,DB01400,Neostigmine
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],14.2,176744,DB01400,Neostigmine
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],8.3,176745,DB01400,Neostigmine
,9044164,volumes of distribution at steady state,Pharmacokinetics of these drugs are dose-independent and have similar volumes of distribution at steady state (0.4-0.6 L/kg various doses).,Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),[l] / [kg],0.4-0.6,191870,DB01400,Neostigmine
,9044164,Inhibitory constants,"Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.",Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),nM,2019,191871,DB01400,Neostigmine
,9044164,Inhibitory constants,"Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.",Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),nM,276,191872,DB01400,Neostigmine
,9044164,Inhibitory constants,"Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.",Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),nM,26,191873,DB01400,Neostigmine
,9044164,Inhibitory constants,"Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.",Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044164/),nM,3.7,191874,DB01400,Neostigmine
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,4.6,192750,DB01400,Neostigmine
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,5.6,192751,DB01400,Neostigmine
,12131108,clearance,"Hypothermia did not change the clearance (696 ml/min), maximum effect, or duration of action of neostigmine.",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),[ml] / [min],696,192752,DB01400,Neostigmine
,1425620,tmax,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,1.9,210774,DB01400,Neostigmine
,1425620,absolute bioavailability,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),%,60,210775,DB01400,Neostigmine
,1425620,terminal elimination half-life,Its terminal elimination half-life is 3.5 h and it is extensively hepatically metabolized.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,3.5,210776,DB01400,Neostigmine
,1425620,Plasma clearance,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [h·kg],0.38,210777,DB01400,Neostigmine
,1425620,volume of distribution,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [kg],1.8,210778,DB01400,Neostigmine
,11881704,retention times,"The retention times for ethambutol, neostigmine bromide, and propranolol are 2.0, 1.4, and 1.1 min, respectively, with a total run time of 2.8 min.","A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),min,2.0,232871,DB01400,Neostigmine
,11881704,retention times,"The retention times for ethambutol, neostigmine bromide, and propranolol are 2.0, 1.4, and 1.1 min, respectively, with a total run time of 2.8 min.","A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),min,1.4,232872,DB01400,Neostigmine
,11881704,retention times,"The retention times for ethambutol, neostigmine bromide, and propranolol are 2.0, 1.4, and 1.1 min, respectively, with a total run time of 2.8 min.","A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),min,1.1,232873,DB01400,Neostigmine
,11881704,total run time,"The retention times for ethambutol, neostigmine bromide, and propranolol are 2.0, 1.4, and 1.1 min, respectively, with a total run time of 2.8 min.","A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),min,2.8,232874,DB01400,Neostigmine
,11881704,detection limits,The detection limits for ethambutol are 0.05 microg/mL for plasma and 0.005 microg/mL for the BAL supernatants and AC suspensions.,"A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),[μg] / [ml],0.05,232875,DB01400,Neostigmine
,11881704,detection limits,The detection limits for ethambutol are 0.05 microg/mL for plasma and 0.005 microg/mL for the BAL supernatants and AC suspensions.,"A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),[μg] / [ml],0.005,232876,DB01400,Neostigmine
,9061114,T1,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,4,246981,DB01400,Neostigmine
,9061114,T1,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,10,246982,DB01400,Neostigmine
,9061114,T1,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,14,246983,DB01400,Neostigmine
,9061114,T1,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,0,246984,DB01400,Neostigmine
,9061114,TOF,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,14,246985,DB01400,Neostigmine
,24115102,flow rate,"The analytes were separated on a Hanbon Hedera CN column (100 × 4.6 mm, 5 µm) with a mobile phase composed of methanol-water (60:40, v/v) and the water containing 0.01% formic acid at a flow rate of 0.6mL/min, with a split ratio of 1:1 flowing 300 μL into the mass spectrometer.",Development and validation of a rapid and high-sensitivity liquid chromatography-tandem mass spectrometry assay for the determination of neostigmine in small-volume beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24115102/),[ml] / [min],0.6,250104,DB01400,Neostigmine
,24115102,run time,The run time was 3 min.,Development and validation of a rapid and high-sensitivity liquid chromatography-tandem mass spectrometry assay for the determination of neostigmine in small-volume beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24115102/),min,3,250105,DB01400,Neostigmine
,24115102,m/,"Detection was accomplished by electrospray ionization source in multiple reactions monitoring mode with the precursor-to-product ion transitions m/z 223.0 → 72.0 and 306.0 → 140.0 for neostigmine and anisodamine (internal standard), respectively.",Development and validation of a rapid and high-sensitivity liquid chromatography-tandem mass spectrometry assay for the determination of neostigmine in small-volume beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24115102/),,223.0,250106,DB01400,Neostigmine
,24115102,m/,"Detection was accomplished by electrospray ionization source in multiple reactions monitoring mode with the precursor-to-product ion transitions m/z 223.0 → 72.0 and 306.0 → 140.0 for neostigmine and anisodamine (internal standard), respectively.",Development and validation of a rapid and high-sensitivity liquid chromatography-tandem mass spectrometry assay for the determination of neostigmine in small-volume beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24115102/),,72,250107,DB01400,Neostigmine
,24115102,m/,"Detection was accomplished by electrospray ionization source in multiple reactions monitoring mode with the precursor-to-product ion transitions m/z 223.0 → 72.0 and 306.0 → 140.0 for neostigmine and anisodamine (internal standard), respectively.",Development and validation of a rapid and high-sensitivity liquid chromatography-tandem mass spectrometry assay for the determination of neostigmine in small-volume beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24115102/),,306.0,250108,DB01400,Neostigmine
,24115102,m/,"Detection was accomplished by electrospray ionization source in multiple reactions monitoring mode with the precursor-to-product ion transitions m/z 223.0 → 72.0 and 306.0 → 140.0 for neostigmine and anisodamine (internal standard), respectively.",Development and validation of a rapid and high-sensitivity liquid chromatography-tandem mass spectrometry assay for the determination of neostigmine in small-volume beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24115102/),,140.0,250109,DB01400,Neostigmine
,8845827,Vdss,"Four ChE inhibitors have similar Vdss values within the range of 0.3-0.7 l/kg, which is similar to the muscle/plasma concentration ratio of these drugs.",Comparative pharmacokinetics of four cholinesterase inhibitors in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845827/),[l] / [kg],0.3-0.7,257133,DB01400,Neostigmine
,8845827,liver,The liver or kidney to plasma concentration ratio of all ChE inhibitors at 20min after i.v. administration ranged from 5 to 15.,Comparative pharmacokinetics of four cholinesterase inhibitors in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845827/),,5 to 15,257134,DB01400,Neostigmine
,8845827,kidney to plasma concentration ratio,The liver or kidney to plasma concentration ratio of all ChE inhibitors at 20min after i.v. administration ranged from 5 to 15.,Comparative pharmacokinetics of four cholinesterase inhibitors in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845827/),,5 to 15,257135,DB01400,Neostigmine
,10690134,onset time,Mean onset time was 66 (SD 24) s.,Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),s,66,260989,DB01400,Neostigmine
,10690134,time to recovery of T1/T0,"In patients who received an antagonist 2 min after the first dose of rapacuronium, time to recovery of T1/T0 to 25% was similar after neostigmine (9.8 (3.8) min) and edrophonium (10.3 (4.3) min): in patients who received incremental doses of rapacuronium, spontaneous recovery of T1/T0 to 25% after the first dose was 18.9 (4.7) min.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,9.8,260990,DB01400,Neostigmine
,10690134,time to recovery of T1/T0,"In patients who received an antagonist 2 min after the first dose of rapacuronium, time to recovery of T1/T0 to 25% was similar after neostigmine (9.8 (3.8) min) and edrophonium (10.3 (4.3) min): in patients who received incremental doses of rapacuronium, spontaneous recovery of T1/T0 to 25% after the first dose was 18.9 (4.7) min.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,10.3,260991,DB01400,Neostigmine
,10690134,spontaneous recovery of T1/T0,"In patients who received an antagonist 2 min after the first dose of rapacuronium, time to recovery of T1/T0 to 25% was similar after neostigmine (9.8 (3.8) min) and edrophonium (10.3 (4.3) min): in patients who received incremental doses of rapacuronium, spontaneous recovery of T1/T0 to 25% after the first dose was 18.9 (4.7) min.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,18.9,260992,DB01400,Neostigmine
,10690134,times to recovery of T4/T1 to,"In those who received an antagonist 2 min after the first dose of rapacuronium, times to recovery of T4/T1 to 0.7 were also similar after neostigmine (23.7 (7.7) min) and edrophonium (29.1 (10.7) min).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,0.7,260993,DB01400,Neostigmine
,10690134,times to recovery of T4/T1 to,"In those who received an antagonist 2 min after the first dose of rapacuronium, times to recovery of T4/T1 to 0.7 were also similar after neostigmine (23.7 (7.7) min) and edrophonium (29.1 (10.7) min).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,23.7,260994,DB01400,Neostigmine
,10690134,times to recovery of T4/T1 to,"In those who received an antagonist 2 min after the first dose of rapacuronium, times to recovery of T4/T1 to 0.7 were also similar after neostigmine (23.7 (7.7) min) and edrophonium (29.1 (10.7) min).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,29.1,260995,DB01400,Neostigmine
,10690134,time to recovery of T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,25,260996,DB01400,Neostigmine
,10690134,time to recovery of T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,5.1,260997,DB01400,Neostigmine
,10690134,time to recovery of T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,3.3,260998,DB01400,Neostigmine
,10690134,recovery to T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,75,260999,DB01400,Neostigmine
,10690134,recovery to T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,10.1,261000,DB01400,Neostigmine
,10690134,recovery to T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,16.8,261001,DB01400,Neostigmine
,10690134,T4/T1,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,0.7,261002,DB01400,Neostigmine
,10690134,T4/T1,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,35.1,261003,DB01400,Neostigmine
,10690134,clearance,"Typical values for clearance and initial volume of distribution (V1) were 4.4 ml kg-1 min-1 and 94.8 ml kg-1, respectively.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),[ml] / [kg·min],4.4,261004,DB01400,Neostigmine
,10690134,initial volume of distribution (V1),"Typical values for clearance and initial volume of distribution (V1) were 4.4 ml kg-1 min-1 and 94.8 ml kg-1, respectively.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),[ml] / [kg],94.8,261005,DB01400,Neostigmine
,7389256,plasma half-life (t1/2),Estimates of plasma half-life (t1/2) ranged from 51.1 to 90.5 min; apparent volume of distribution varied from 32.0 to 60.6 1; and total body clearance from 434 to 549 ml/min.,Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389256/),min,51.1 to 90.5,266620,DB01400,Neostigmine
,7389256,apparent volume of distribution,Estimates of plasma half-life (t1/2) ranged from 51.1 to 90.5 min; apparent volume of distribution varied from 32.0 to 60.6 1; and total body clearance from 434 to 549 ml/min.,Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389256/),1,32.0 to 60.6,266621,DB01400,Neostigmine
,7389256,total body clearance,Estimates of plasma half-life (t1/2) ranged from 51.1 to 90.5 min; apparent volume of distribution varied from 32.0 to 60.6 1; and total body clearance from 434 to 549 ml/min.,Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389256/),[ml] / [min],434 to 549,266622,DB01400,Neostigmine
,7389256,t1/2,"The neostigmine t1/2, based on the urinary excretion of the unchanged drug, ranged from 90.2 to 118.7 min.",Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389256/),min,90.2 to 118.7,266623,DB01400,Neostigmine
